Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Single-Dose, Open Label, Parallel Design, Controlled Pharmacology Trial of Fumaryl Diketopiperazine Administered as Technosphere Inhalation Power in Subjects With Either Mild or Moderate Chronic Kidney Disease vs. Matched Subjects Without Chronic Kidney Disease

NCT00626249 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.

NCT NCT00626249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Single-Dose, Open Label, Parallel Design, Controlled Pharmacology Trial of Fumaryl Diketopiperazine Administered as Technosphere Inhalation Power in Subjects With Either Mild or Moderate Chronic Kidney Disease vs. Matched Subjects Without Chronic Kidney Disease
Lead sponsor
Mannkind Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2007
Completion date
October 31, 2008
Enrollment
36 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, mild nephropathy, moderate nephropathy